In the NEJ027 study, dose adjustments (78.9%) were common in older Japanese patients with EGFR mutation-positive NSCLC, but treatment discontinuation (21.1%) was rare, allowing most to continue treatment for over a year [33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.